We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice buying today, lots of bombed out Bio's/Pharma showing life atm
5m = cash
2m = mcap
Ask rising steadily
Cash runway until April 24. Question is whether they will be able to announce anything before then to entice investors to stump up more money. It's looking doubtful
Seems major pharma have an interest in the field:
https://exosome-rna.com/featured-exosome-job-sr-scientist-exosomes/
If you are waiting for a substantial rise, you will have a very long wait I have had these shares for over twenty years nothing but broken promises Rene should have this wrote on there tomb stone here lies Rene and lies and lies and lies for evermore.
Hi Sajy,
You used to post some quite bullish messages on this board not so long ago but there's been nothing from you for a while. Have you given up on Rene? In the absence of any RNS update from the company, do you have any thoughts on Rene's prospects?
They may well be but RENE have moved a bit away from stem cells in the last two years. Perhaps something else is also the future?
Added some more at 3.7p today
3.7-4p but you can buy online at 3.808p at the moment like the 50k has just done. Pretty good value, they were all over this 2 weeks ago at 4.2-4.5p when it was moving so this price looks decent if it can clear the overhang
3.85 pence As a punt. The trouble is red tape ties progress up, if you have some small change in your pocket, why not have ago your mother did. Stem cells are a thing of the future.
How much lower? Answer has low as a snakes boll cks they don,t come any lower then that.
How many phases does Rene have to pass to make this a viable invesment plus how long does each phase take, I have held these shares for over twenty years my time on earth is very precious this share has been nothing but atrocious to say the least. Stay away I wish i had!
Thanks Theoldmasdoneit. It looks like this news is now splashed all over the media. Reneuron's Chair of the Scientific Advisory Board, Stephano Pluccino, who was a co-author on the paper, has even been interviewed by ITV:
https://www.itv.com/news/2023-11-27/ms-breakthrough-could-lead-to-treatments-that-halt-diseases-progression
They did not use Reneuron's stem cell lines for this work but a similar source from Italy that, as far as I'm aware, has not been immortalised (it's worth fact-checking this). As Stephano stresses, it's only at the Phase 1 safety stage, but the stem cell/exosome area may pique investor interest again.
Https://neurosciencenews.com/stem-cells-multiple-sclerosis-25257/#:~:text=What%20is%20this%3F&text=An%20international%20team%20has%20shown,the%20brain%20from%20further%20damage.
From the Reneuron RNS 8th November,
'The Group ended the period to 30 September 2023 with cash, cash equivalents and bank deposits of £5.1 million with the cash runway being extended into the start of calendar Q2 2024.'
No mention of Q125.
Give it a few days. It might have some impact then.
Alternatively, the market might only be interested in seeing deals now. Which will provide solid proof that the potential is real and the company is worthy of investment/further investment. GLA while we wait!
Year dates all wrong.
"As of 30 September 2023, Reneuron had cash balance of £5.1m, which we estimate should fund operations into 'Q125', consistent with management's expected cash runway to April 2024" ????
More errors in the Full Report.
Technology making the world dumber.
Not much interest in their not valuing at 52p :(((
Used to hold this about 5 years ago and sold at a small loss. The performance since is a bit alpine really isnt it. The £2.4m tiny MCAP may make it ripe for a buy out I think...
4 v 1 on L2 next offer 5p but all gone quiet but I'm going to hold a while, I think it can get back to 6-10p range again for a nice short term profit
Thanks Chester, I'll get my yacht on order for delivery Q1 2030 in that case!
Hi Phil
From : PharmaWeb.com
'What is the market for exosome diagnostics and therapeutics?'
According to the report, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.
So it shows that there is definitely a growing market for a Fully Working Exosome Platform.
Chester.
Chester - the question I keep coming back to in my head is why the deals for exosomes appear to have dried up? There was a relative flurry of deals around 2018 to 2020, but nothing substantive since. Is it that exosomes aren't seen as a viable option for whatever reason (scalability, consistency etc)? Or is it that the first generation HEK derived exosomes (that the pre clinical deals were done on for codiak and evox etc) were found to have significant limitations?
If it's the former, then they may as well just pull the plug now. If it's the latter, then perhaps Rene is sitting on something huge that the industry has been waiting for. Proof will be in the pudding, and we will presumably find out one way or another in the next couple of months.
The attraction of this share is the potential upside if any positive news does land.
What we do know is that Exosomes have the potential to improve the targeted delivery of some drugs that lack the precision to find their designated human cells.
We also know that some fairly sizeable deals have already been made and Exosomes that achieve their potential will be worth £10M's.
Reneuron may have just proved that their Exosomes are some of the best in class.
Obviously proved in their own labs but interested parties must be examining the data.
My opinion is that they have better than a 50/50 chance to do a deal before next February/ March.
Added to these assumptions is that the market Capitalisation is so low that the Assets, Patents and Intellectual Property are probably worth much more.
Chester18.